Lenalidomid Teva (Lenalidomide)

Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase, leading to selective degradation of transcription factors that regulate cell survival. This results in immune modulation, inhibition of new blood‑vessel formation, and promotion of programmed cell death in malignant cells.

The specific dose of Lenalidomid Teva is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and other individual factors. Only a qualified healthcare professional should set the dosing schedule.

Lenalidomid Teva is classified as teratogenic and is contraindicated in pregnancy. Women of child‑bearing potential must use effective contraception. Safety during breastfeeding has not been established, and breastfeeding is generally not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomid Teva belongs to the immunomodulatory drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It is often used in combination regimens and may provide benefits in disease control and progression‑free survival, though choice of therapy depends on individual patient factors and physician judgment.

Lenalidomid Teva should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight to maintain stability throughout its shelf life.

Lenalidomid Teva is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. Patients should follow the exact schedule and instructions provided by their healthcare professional.

Serious risks include venous thromboembolism, severe neutropenia leading to infection, secondary primary malignancies, hepatic toxicity, and rare pulmonary complications such as interstitial lung disease. Patients should be monitored closely for these events.

Lenalidomid Teva should not be used by individuals with known hypersensitivity to lenalidomide or any excipients, pregnant women, or patients with severe renal impairment unless dose adjustments are made. It is also contraindicated in patients with active uncontrolled infections.